AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Observe Medical

Major Shareholding Notification Oct 13, 2025

3696_mrq_2025-10-13_9962c527-df77-48bb-815d-d30572cf717f.html

Major Shareholding Notification

Open in Viewer

Opens in native device viewer

Observe Medical ASA: Disclosure of major shareholdings following completion of the Private Placement and Subsequent Offering

Observe Medical ASA: Disclosure of major shareholdings following completion of the Private Placement and Subsequent Offering

Reference is made to the stock exchange announcements published by Observe

Medical ASA (the "Company") regarding (i) the issuance of 20,000,000 new shares

to complete the private placement at the extraordinary general meeting held on

10 October 2025 (the "Private Placement"), and (ii) the final result of the

subsequent offering announced on 13 October 2025 (the "Subsequent Offering").

Following completion of the Private Placement, the total number of shares in the

Company will be 112,148,412. Following completion and registration of both the

Private Placement and the Subsequent Offering, the total number of shares in the

Company will be 136,148,412, each with a nominal value of NOK 0.42.

Subject to the completion of the Private Placement and the Subsequent Offering,

the following shareholders have crossed disclosure thresholds pursuant to

section 4-2 of the Norwegian Securities Trading Act:

· Songa Capital AS will hold 10,000,000 shares in the Company and Songa X AS

will hold 2,500,000 shares in the Company, jointly representing 11.15% of the

share capital and votes in the Company following the Private Placement and

before the Subsequent Offering, and 9.18% of the share capital and votes in the

Company after the final allocation of the Subsequent Offering, consequently

crossing the disclosure threshold of 5% of the votes in the Company.

· Navamedic ASA held 12,564,279 shares, representing 13.63% of the share

capital and votes prior to the Private Placement and the Subsequent Offering.

Following completion of the Private Placement, Navamedic ASA will hold 11.20%,

and after the Subsequent Offering 9.23%, and has therefore fallen below the 10%

disclosure threshold.

· R Investment Company AS held 10,103,571 shares, representing 10.96% of the

share capital and votes prior to the Private Placement and the Subsequent

Offering. Following completion of the Private Placement, R Investment Company AS

will hold 9.01% of the share capital and votes, and after the Subsequent

Offering R Investment Company AS will hold 10,703,684 shares, representing 7.86%

of the share capital and votes, and has therefore fallen below the 10%

disclosure threshold.

· Seed Capital AS held 5,016,155 shares, representing 5.44% of the share

capital and votes prior to the Private Placement and the Subsequent Offering.

Following completion of the Private Placement, Seed Capital AS will hold 4.47%

of the share capital and votes, and after the Subsequent Offering Seed Capital

AS will hold 5,236,268 shares, representing 3.85% of the share capital and

votes, and has therefore fallen below the 5% disclosure threshold.

· Jiangsu Hongxin Medical Technology Co., Ltd. held 6,000,000 shares,

representing 6.51% of the share capital and votes prior to the Private Placement

and the Subsequent Offering. Following completion of the Private Placement,

Jiangsu Hongxin Medical Technology Co., Ltd. will hold 5.35% of the share

capital and votes, and after the Subsequent Offering Jiangsu Hongxin Medical

Technology Co., Ltd  will hold 6,000,000 shares, representing 4.41% of the share

capital and votes, and has therefore fallen below the 5% disclosure threshold.

The changes in shareholdings are due solely to dilution and/or the allocation of

new shares in connection with the Private Placement and the Subsequent Offering,

and not to any other direct acquisition or disposal of shares.

This disclosure is made pursuant to section 4-2 of the Norwegian Securities

Trading Act.

Talk to a Data Expert

Have a question? We'll get back to you promptly.